PONTE
VEDRA, Fla., Jan. 4, 2024
/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a
biopharmaceutical company developing tecarfarin, a late-stage novel
oral and reversible anticoagulant (blood thinner) designed to
prevent heart attacks, strokes and deaths due to blood clots in
patients with certain conditions, announced today that the Company
will present at Biotech Showcase™ 2024, alongside the J.P. Morgan
42nd Annual Healthcare Conference.
Presenter: Quang Pham, CEO of
Cadrenal Therapeutics
Date: Monday, January 8, 2024 at
10:00am PT (1:00pm ET)
Location: Yosemite-C Room, Hilton San Francisco Union Square,
San Francisco, CA
Registration: Here
"We are excited to present details of tecarfarin, a late-stage
drug with orphan drug and Fast Track designations, at the Biotech
Showcase next week in San
Francisco," commented Quang
Pham, CEO of Cadrenal.
Tecarfarin is a novel chemical entity that is designed to
provide stable anticoagulation to patients with certain orphan
diseases, including End-Stage Kidney Disease (ESKD) with Atrial
Fibrillation (AFib); Left Ventricular Assist Devices (LVADs); and
Antiphospholipid Syndrome (APS). Tecarfarin was specifically
designed to be metabolized via an alternate pathway than warfarin –
a metabolic pathway that is abundant and essentially insaturable,
providing a more reliable pharmacokinetic profile than
warfarin.
"Tecarfarin is targeted for indications where warfarin fails to
achieve sufficiently stable anticoagulation and DOACs, or the
Eliquis-class of drugs, have clinically not shown benefit," Pham
expanded. "Tecarfarin provides a more stable anticoagulation than
warfarin due to its metabolism, thereby decreasing the risk of
stroke and bleeding."
Management will be participating in one-on-one meetings
throughout the event. To arrange a meeting with management, please
contact your Biotech Showcase representative or Lytham Partners at
CVKD@lythampartners.com.
Prior to presenting, Pham will participate in a special Opening
Bell ceremony on Monday, January 8,
2024 at the Nasdaq Entrepreneurial Center in
San Francisco. The ceremony
will feature healthcare companies within the Nasdaq Biotechnology
Index, highlighting them as companies pioneering the future.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an
investor conference focused on driving advances in therapeutic
development by providing a sophisticated networking platform for
executives and investors that fosters investment and partnership
opportunities. The conference takes place each year in San Francisco during the course of one of the
industry's largest gatherings and busiest weeks.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal
Therapeutics is developing tecarfarin, a late-stage novel oral and
reversible anticoagulant (blood thinner), to prevent heart attacks,
strokes, and deaths due to blood clots in patients with certain
conditions. Tecarfarin has orphan drug and fast track designations
for the prevention of systemic thromboembolism (blood clots) of
cardiac origin in patients with end stage kidney disease (ESKD) and
atrial fibrillation (AFib). Tecarfarin is specifically designed to
leverage a different metabolism pathway than the oldest and most
commonly prescribed Vitamin K Antagonist (warfarin). Tecarfarin has
been evaluated in eleven (11) human clinical trials and more than
1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical
trials, tecarfarin has generally been well-tolerated in both
healthy adult subjects and patients with chronic kidney disease.
For more information, please visit: www.cadrenal.com.
Safe Harbor Statement
Any statements contained in this
press release about future expectations, plans and prospects, as
well as any other statements regarding matters that are not
historical facts, may constitute "forward-looking statements."
These statements include statements regarding tecarfarin's ability
to provide stable anticoagulation to patients with certain
conditions, including End-Stage Kidney Disease (ESKD) with Atrial
Fibrillation (AFib); Left Ventricular Assist Devices (LVADs); and
Antiphospholipid Syndrome (APS).
The words "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including the ability to advance
tecarfarin within patients with ESKD, AFib, LVADs and APS and the
other risk factors described in the Company's Annual Report on Form
10-K for the year ended December 31,
2022, and the Company's subsequent filings with the SEC,
including subsequent periodic reports on Quarterly Reports on Form
10-Q and Current Reports on Form 8-K. Any forward-looking
statements contained in this press release speak only as of the
date hereof and, except as required by federal securities laws, the
Company specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-present-at-the-biotech-showcase-on-january-8-2024-alongside-the-jp-morgan-annual-healthcare-conference-302025890.html
SOURCE Cadrenal Therapeutics, Inc.